Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs
description
Transcript of Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs
![Page 1: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/1.jpg)
Pre-operative Imatinib for Pre-operative Imatinib for metastatic, recurrent and metastatic, recurrent and
locally advanced GISTslocally advanced GISTs
E. Efthimiou, S MudanE. Efthimiou, S Mudan
On behalf of the Sarcoma GroupOn behalf of the Sarcoma Group
The Royal Marsden HospitalThe Royal Marsden Hospital
![Page 2: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/2.jpg)
IncidenceIncidence
• Gastrointestinal Stromal Tumours GIST Gastrointestinal Stromal Tumours GIST are the most common mesenchymal are the most common mesenchymal tumours of the gastrointestinal tract. tumours of the gastrointestinal tract.
• The incidence is 15 to 20 cases per The incidence is 15 to 20 cases per million population per year for million population per year for symptomatic and clinically detected symptomatic and clinically detected GIST.GIST.
Kindblom, LG et al : Ann Oncol 2002: 13 (Suppl 5):157, 2002.Kindblom, LG et al : Ann Oncol 2002: 13 (Suppl 5):157, 2002.
![Page 3: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/3.jpg)
Organ distributionOrgan distribution
Stomach - 70% Stomach - 70%
Small bowel - 20% Small bowel - 20%
Colorectum, oesophagus, EGIST - Colorectum, oesophagus, EGIST - 10%.10%.
![Page 4: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/4.jpg)
Omental GISTOmental GIST Gastric GISTGastric GIST
![Page 5: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/5.jpg)
Gastric GISTGastric GIST Gastric GISTGastric GIST
![Page 6: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/6.jpg)
BackgroundBackground• Surgical resection is feasible in Surgical resection is feasible in
approximately two thirds of patients approximately two thirds of patients with primary non-metastatic disease. with primary non-metastatic disease.
• Approximately half of these patients Approximately half of these patients eventually develop intra-peritoneal eventually develop intra-peritoneal recurrence or liver metastases. recurrence or liver metastases.
• The 5- and 10-year survival after The 5- and 10-year survival after curative resection is 32% to 78% and curative resection is 32% to 78% and 19% to 63%, respectively.19% to 63%, respectively.
Roberts PJ,et al Eur J Cancer 2002Roberts PJ,et al Eur J Cancer 2002
Lehnet T, et al Ann Chir Gynaecol 2003Lehnet T, et al Ann Chir Gynaecol 2003
![Page 7: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/7.jpg)
BackgroundBackground
• Imatinib is the effective therapy for Imatinib is the effective therapy for metastatic and inoperable GIST.metastatic and inoperable GIST.
• A sufficient down staging may allow A sufficient down staging may allow surgical resection either with a surgical resection either with a curative intent before or at the time curative intent before or at the time of resistance. of resistance.
![Page 8: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/8.jpg)
BackgroundBackground
• Stable disease rate 30%Stable disease rate 30%
• Partial response rate 50%Partial response rate 50%
• Complete response rate 2%. Complete response rate 2%.
![Page 9: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/9.jpg)
PatientsPatients
• Twenty five cases of locally Twenty five cases of locally advanced primary, recurrent or advanced primary, recurrent or metastatic GIST treated metastatic GIST treated preoperatively with Imatinib were preoperatively with Imatinib were identified from the sarcoma database identified from the sarcoma database in our Unit.in our Unit.
![Page 10: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/10.jpg)
DesignDesign• Sex, race, age at presentation.Sex, race, age at presentation.
• Site of primary tumour and extent of Site of primary tumour and extent of disease at presentation.disease at presentation.
• Dose of Imatinib prior to the operation, Dose of Imatinib prior to the operation, side effects and duration of treatment. side effects and duration of treatment.
• Maximal tumour diameter and Maximal tumour diameter and radiological response.radiological response.
• Surgical procedure and completeness Surgical procedure and completeness of resection.of resection.
• Disease status at last follow-up.Disease status at last follow-up.
![Page 11: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/11.jpg)
GenderGender
13 female12 male
![Page 12: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/12.jpg)
Site of primary tumour originSite of primary tumour origin
0GJ
Small bowel
Gastric greater curveGastric lesser curve
rectum
10
8
12
4
![Page 13: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/13.jpg)
State of response at the time State of response at the time of of surgery surgery
Stable disease
20
Progressive disease
5
progression
stable
![Page 14: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/14.jpg)
Histological GradeHistological Grade
High
20
Intermediate
4
Low1
![Page 15: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/15.jpg)
Pathologic response to Pathologic response to ImatinibImatinib
No resection 3No response 2Partial response 20
![Page 16: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/16.jpg)
ResectionResection
R1OCR0R2
13 pts (52%)
6 pts (24%)3pts (12%)
3pts (12%)
![Page 17: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/17.jpg)
Recurent/metastatic Recurent/metastatic Locally advancedLocally advanced
• Number ofpatients Number ofpatients 7 7 1818
• Male/Female Male/Female 1/6 1/6 11/711/7
• Median age at diagnosisMedian age at diagnosis 48 63 48 63
• Side effects of Imatinib 7 Side effects of Imatinib 7 11 11
Diarrhea 1 3Diarrhea 1 3
Rash 1 5Rash 1 5
Neutropenia 1 -Neutropenia 1 -
Peri-orbital oedema 4 4Peri-orbital oedema 4 4
Indigestion 2 2 Indigestion 2 2
Pleural effusion 1 -Pleural effusion 1 -
Ankle edema - 3Ankle edema - 3
• Pre Imatinib diameterPre Imatinib diameter 6.7cm 6.7cm 14.1cm14.1cm
• Post imatinib diameterPost imatinib diameter 6.6cm 6.6cm 9.8cm 9.8cm
![Page 18: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/18.jpg)
Recurent/metastatic Recurent/metastatic Locally advancedLocally advanced
• Pathological responsePathological response
• Partial response 5 15Partial response 5 15
• No response 2 -No response 2 -
• Tumour not resected - 3Tumour not resected - 3
• Median Glivec DurationMedian Glivec Duration 27 months (range 6-62) 9 months 27 months (range 6-62) 9 months (range 5-32)(range 5-32)
• Median Overall survivalMedian Overall survival 46 months (range 20-77) 9.5 months 46 months (range 20-77) 9.5 months (range 5-52) (range 5-52)
• Disease status at follow upDisease status at follow up
• Disease free 2 11Disease free 2 11
• Liver and peritoneal metastases 3 4 Liver and peritoneal metastases 3 4
• Primary disease - 2Primary disease - 2
• Dead 2 1 Dead 2 1
![Page 19: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/19.jpg)
Postoperative survival in Postoperative survival in metastatic and recurrent metastatic and recurrent versus locally advanced GISTSversus locally advanced GISTS
Locally advanced GISTs 94%
Reccurent/metastaticGISTS 71%
![Page 20: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/20.jpg)
Survival and site of origin of Survival and site of origin of primary GISTprimary GIST
77%
![Page 21: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/21.jpg)
Gastric GISTsGastric GISTs
33%
90%
![Page 22: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/22.jpg)
Survival and extent of Survival and extent of resectionresection
50%
![Page 23: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/23.jpg)
Survival in R2 resectionsSurvival in R2 resections
![Page 24: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/24.jpg)
Survival and pathologic Survival and pathologic responseresponse
50%
90%
90%
50%
![Page 25: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/25.jpg)
Post operative survival and Post operative survival and status of response at status of response at operationoperation
90%
80%
![Page 26: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/26.jpg)
Overall survivalOverall survival
Median 32monts (range 8-77 months)
![Page 27: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/27.jpg)
Summary 1Summary 1
• 2/7 of the metastatic and recurrent 2/7 of the metastatic and recurrent GIST patients achieved macroscopic GIST patients achieved macroscopic clearance .clearance .
• 5/7 alive after a median period of 46 5/7 alive after a median period of 46 months (range 20-77)months (range 20-77)
![Page 28: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/28.jpg)
Summary 2Summary 2
• 94% of the locally advanced group 94% of the locally advanced group are alive at median FU 9.5 monthsare alive at median FU 9.5 months
(range 5-52).(range 5-52).
• Median duration on Imatinib was 27 Median duration on Imatinib was 27 months for recurrent and metastatic months for recurrent and metastatic GIST versus 9 months for locally GIST versus 9 months for locally advanced.advanced.
![Page 29: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/29.jpg)
Summary 3Summary 3
• R2 resection was associated with R2 resection was associated with worse survival.worse survival.
• Absence of pathological response Absence of pathological response was associated with 50% survival was associated with 50% survival versus 90% for partial response.versus 90% for partial response.
![Page 30: Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs](https://reader036.fdocuments.net/reader036/viewer/2022062408/56813fd9550346895daabf8b/html5/thumbnails/30.jpg)
Conclusions
• Recurrent /metastatic patients Recurrent /metastatic patients required longer duration of treatment required longer duration of treatment before surgery and were less likely to before surgery and were less likely to achieve the goal of complete achieve the goal of complete macroscopic clearance.macroscopic clearance.
• Hence the survival was inferior to the Hence the survival was inferior to the locally advanced group.locally advanced group.